During the recent session, Synthetic Biologics Inc. (AMEX:SYN)’s traded shares were 3.08 million, with the beta value of the company hitting 1.83. At the last check today, the stock’s price was $0.66, reflecting an intraday loss of -7.97% or -$0.06. The 52-week high for the SYN share is $1.70, that puts it down -157.58 from that peak though still a striking 60.61% gain since the share price plummeted to a 52-week low of $0.26. The company’s market capitalization is $93.35M, and the average intraday trading volume over the past 10 days was 4.86 million shares, and the average trade volume was 6.62 million shares over the past three months.
Synthetic Biologics Inc. (SYN) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. SYN has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.02.
Synthetic Biologics Inc. (AMEX:SYN) trade information
Synthetic Biologics Inc. (SYN) registered a -7.97% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -7.97% in intraday trading to $0.66 this Thursday, 06/10/21, hitting a weekly high. The stock’s 5-day price performance is 25.22%, and it has moved by 38.76% in 30 days. Based on these gigs, the overall price performance for the year is 61.04%. The short interest in Synthetic Biologics Inc. (AMEX:SYN) is 0.78 million shares and it means that shorts have 0.29 day(s) to cover.
The consensus price target of analysts on Wall Street is $1.88, which implies an increase of 64.89% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.25 and $2.50 respectively. As a result, SYN is trading at a discount of -278.79% off the target high and -89.39% off the low.
Synthetic Biologics Inc. (SYN) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 88.90% this quarter and then jump 85.70% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 48.90%. While earnings are projected to return 32.50% in 2021.
Synthetic Biologics Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Synthetic Biologics Inc. (AMEX:SYN)’s Major holders
Synthetic Biologics Inc. insiders own 1.78% of total outstanding shares while institutional holders control 6.50%, with the float percentage being 6.62%. Blackrock Inc. is the largest shareholder of the company, while 38 institutions own stock in it. As of Mar 30, 2021, the company held over 2.35 million shares (or 1.78% of all shares), a total value of $1.6 million in shares.
The next largest institutional holding, with 2.01 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 1.53% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $1.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of Synthetic Biologics Inc. (SYN) shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. Data provided on Mar 30, 2021 indicates that Vanguard Extended Market Index Fund owns about 1.95 million shares. This amounts to just over 1.48 percent of the company’s overall shares, with a $1.33 million market value. The same data shows that the other fund manager holds slightly less at 0.69 million, or about 0.52% of the stock, which is worth about $0.47 million.